Time to RCC recurrence prognostic threshold challenged
A large study confirms the prognostic value of time to recurrence after surgery for renal cell carcinoma, and also suggests the need to reduce the threshold for early recurrence. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 28, 2013 Category: Cancer & Oncology Source Type: news
Findings support partial nephrectomy for T1b RCC
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 28, 2013 Category: Cancer & Oncology Source Type: news
TORS ‘viable’ and preserves QoL in oropharyngeal cancer
Patients with oropharyngeal squamous cell carcinoma who are treated with transoral robotic surgery maintain a high quality of life at 1-year post-surgery, a prospective study indicates (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 21, 2013 Category: Cancer & Oncology Source Type: news
Diabetes plus obesity increases RCC recurrence risk
Patients with renal cell carcinoma are at increased risk for recurrence following surgery if they also have Type 2 diabetes, a retrospective analysis shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 15, 2013 Category: Cancer & Oncology Source Type: news
Survival still poor in non-clear cell RCC despite targeted therapies
Even in the era of targeted therapy, most patients with non-clear cell renal cell carcinoma still have inferior survival compared with their clear-cell counterparts, despite outcomes being significantly improved, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 13, 2013 Category: Cancer & Oncology Source Type: news
Tumor size key to visceral pleural invasion impact
Visceral pleural invasion significantly increases the risk for recurrence and reduces overall survival (OS) in patients with non-small-cell lung cancer, but only for those whose tumors are over 2 cm in diameter, research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 7, 2013 Category: Cancer & Oncology Source Type: news
NSCLC BRAF mutation characterized in the clinic
Clinical characteristics do not distinguish between non-small-cell lung cancer patients with and without BRAF mutations, report US scientists. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 7, 2013 Category: Cancer & Oncology Source Type: news
Afatinib effective in erlotinib/gefitinib-resistant NSCLC
Afatinib is effective when given to patients with non-small-cell lung cancer who have progressed during treatment with erlotinib and/or gefitinib, phase II trial results reveal. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 2, 2013 Category: Cancer & Oncology Source Type: news
Afatinib could become standard first-line option for metastatic NSCLC
Afatinib significantly prolongs progression-free survival in patients with metastatic lung adenocarcinoma and epidermal growth factor mutations, a phase III trial has found. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 2, 2013 Category: Cancer & Oncology Source Type: news
Major European study finds air pollution–lung cancer link
Exposure to ambient air pollution is associated with an increased risk for lung cancer, particularly adenocarcinoma, a large European cohort study indicates. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 30, 2013 Category: Cancer & Oncology Source Type: news
Cytoreductive nephrectomy for small RCC tumors questioned
Researchers have found that cytoreductive radiofrequency ablation plus sunitinib offers limited benefits over sunitinib alone in the treatment of small tumors in patients with metastatic renal cell carcinoma. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 29, 2013 Category: Cancer & Oncology Source Type: news
ROS1 rearrangement ‘specific for lung cancer in never-smokers’
Lung adenocarcinomas harboring genetic rearrangements of the receptor tyrosine kinase proto-oncogene ROS1 are more frequent in people who have never smoked than in smokers, a study by South Korean researchers shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 29, 2013 Category: Cancer & Oncology Source Type: news
Pemetrexed–bevacizumab effective maintenance therapy for NSCLC
Pemetrexed in combination with bevacizumab is superior to bevacizumab alone when given as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer, results of the AVAPERL trial show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 29, 2013 Category: Cancer & Oncology Source Type: news
Pemetrexed maintenance therapy prolongs survival in nonsquamous NSCLC
Pemetrexed maintenance therapy offers a survival benefit over placebo and is well tolerated in patients with advanced nonsquamous non-small-cell lung cancer, final results of the PARAMOUNT trial show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 26, 2013 Category: Cancer & Oncology Source Type: news
Intercalated regimen demonstrates first-line efficacy for advanced NSCLC
Administration of erlotinib in combination with chemotherapy is a viable first-line treatment strategy in patients with advanced non-small-cell lung cancer, results from FASTACT-2 suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 26, 2013 Category: Cancer & Oncology Source Type: news
